- Home
- FHTX vs PAII Comparison
FHTX vs PAII Comparison
Compare FHTX & PAII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FHTX
- PAII
- Stock Information
- Founded
- FHTX 2015
- PAII 2025
- Country
- FHTX United States
- PAII United States
- Employees
- FHTX N/A
- PAII N/A
- Industry
- FHTX Medicinal Chemicals and Botanical Products
- PAII
- Sector
- FHTX Health Care
- PAII
- Exchange
- FHTX Nasdaq
- PAII Nasdaq
- Market Cap
- FHTX 278.1M
- PAII 271.3M
- IPO Year
- FHTX 2020
- PAII 2025
- Fundamental
- Price
- FHTX $4.23
- PAII $10.06
- Analyst Decision
- FHTX Strong Buy
- PAII
- Analyst Count
- FHTX 5
- PAII 0
- Target Price
- FHTX $11.80
- PAII N/A
- AVG Volume (30 Days)
- FHTX 270.7K
- PAII 120.9K
- Earning Date
- FHTX 10-31-2025
- PAII 01-01-0001
- Dividend Yield
- FHTX N/A
- PAII N/A
- EPS Growth
- FHTX N/A
- PAII N/A
- EPS
- FHTX N/A
- PAII N/A
- Revenue
- FHTX $24,173,000.00
- PAII N/A
- Revenue This Year
- FHTX $42.43
- PAII N/A
- Revenue Next Year
- FHTX $14.77
- PAII N/A
- P/E Ratio
- FHTX N/A
- PAII N/A
- Revenue Growth
- FHTX N/A
- PAII N/A
- 52 Week Low
- FHTX $2.95
- PAII $9.92
- 52 Week High
- FHTX $9.70
- PAII $10.10
- Technical
- Relative Strength Index (RSI)
- FHTX 45.28
- PAII N/A
- Support Level
- FHTX $3.85
- PAII N/A
- Resistance Level
- FHTX $4.69
- PAII N/A
- Average True Range (ATR)
- FHTX 0.33
- PAII 0.00
- MACD
- FHTX 0.04
- PAII 0.00
- Stochastic Oscillator
- FHTX 55.77
- PAII 0.00
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
About PAII Pyrophyte Acquisition Corp. II Class A Ordinary Shares
Pyrophyte Acquisition Corp II is a special purpose acquisition company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.